phosphoinositide-3 kinase inhibitors (Intellikine)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namephosphoinositide-3 kinase inhibitors (Intellikine)
Drug Alias NameINK-1138
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphatidylinositol 3 kinase gamma inhibitorsPhosphatidylinositol 3 kinase beta inhibitorsPhosphatidylinositol 3 kinase delta inhibitors
TargetsPhosphatidylinositol-4,5-Bisphosphate 3 kinase gammaPhosphatidylinositol 3 kinase betaPhosphatidylinositol 3 kinase delta
Therapy Area/IndicationsInflammationAutoimmune DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIntellikine LLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIntellikine LLC
Active IndicationsN/A
Inactive IndicationsInflammationAutoimmune DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A